| |
Wednesday 2 September 2015
| 08:00 - 15:00
| D203 |
| 08:00 - 09:45 | Robustness and generalisability |
| |
| 08:00 - 08:30 | Robustness and generalisability in the context of preclinical drug development |
| | speaker: | Thomas Steckler, Belgium |
| |
| 08:30 - 09:00 | Generalisability to man: can we use comparable readouts preclinically and in patients? |
| | speaker: | Martien Kas, Netherlands |
| |
| 09:00 - 09:30 | NIH's efforts to assess generalisability – identifying the need to include female experimental subjects |
| | speaker: | Elena Koustova, United States |
| |
| 10:15 - 12:00 | The utility of biomarkers to enhance robustness and generalisability preclinically and in the clinic |
| | | Gary Gilmour, United Kingdom |
| |
| 10:15 - 10:45 | Validating preclinical biomarkers in psychiatry - a mechanism-based approach |
| | speaker: | Andreas Meyer-Lindenberg, Germany |
| |
| 10:45 - 11:15 | Pillars of success approach to predict success of proof-of-concept phase II studies |
| | speaker: | t.b.a. |
| |
| 11:15 - 11:45 | Biomarker development from a quality perspective |
| | speaker: | Lee Monk, United Kingdom |
| |
| 13:00 - 14:45 | Data sharing – current status and next steps |
| |
| 13:00 - 13:30 | A proposal for a new data sharing mechanism for the preclinical data forum network |
| | speaker: | Magali Haas, United States |
| |
| 13:30 - 14:00 | Data sharing in a public private partnership context: the innovative medicines initiative experience |
| | speaker: | Elisabetta Vaudano, Belgium |
| |
| 14:00 - 14:30 | An update on European academic initiatives |
| | speaker: | Malcolm McLeod, United Kingdom |
| |
| 14:45 - 15:00 | General discussion and closing |